BioSpace News Archive

The World Anti-Microbial Resistance Congress 2019 was held November 7-8 in Washington, D.C.

Secarna Pharmaceuticals, a new breed of biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide therapies to address challenging or previously undruggable targets, announced that the Company has completed a financing round, which was open only to existing investors.

The merged company will be led by David Domzalski, current chief executive officer of Foamix. It will be headquartered in New Jersey.

Announces “Functional to FFPE” Early-Access Grant Program

Lytix Biopharma AS announces a clinical collaboration with the US-based company Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte technology, to evaluate Lytix`s first-in-class oncolytic peptide, LTX-315, in combination with Iovance`s autologous ready to infuse T cell therapy.

London: Monday, November 11, 2019: Hutchison China MediTech Limited announces that Christian Hogg, Chief Executive Officer, will present at the following conferences

The drug failed to meet the primary endpoints of progression-free survival and overall response rate.

Genentech announced this morning that its experimental SMA drug risdiplam hit the mark in the second part of the pivotal SUNFISH study of patients with Type 2 and 3 of the disease.

Both DISCOVER 1 and DISCOVER 2 are evaluating Tremfya in adults with active psoriatic arthritis.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that it received $10M upfront for a License Agreement with UroGen Pharma Ltd.